3,511 results found

Teva Pharmaceutical Industries and Samsung Bioepis have expanded their biosimilar partnership to include up to six new biosimilar candidates. Two confirmed candidates are SB41, referencing AstraZeneca's FASENRA (benralizumab) for eosinophilic asthma, and SB44, referencing Novartis's ILARIS (canakinumab) for systemic juvenile idiopathic arthritis and other inflammatory conditions.

On July 3, the Government of Ontario announced that by October 2019, 50 new retail cannabis stores will be authorized to open in Ontario on a rolling basis